Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Elixir Department: SOP for Endotoxin Testing – V 2.0

Posted on By

Elixir Department: SOP for Endotoxin Testing – V 2.0

Standard Operating Procedure for Endotoxin Testing in Elixir Formulations

Department Elixir Department
SOP No. SOP/ELX/229/2025
Supersedes SOP/ELX/229/2022
Page No. Page 1 of 8
Issue Date 11/04/2025
Effective Date 15/04/2025
Review Date 11/04/2026

1. Purpose

To establish a validated and standardized procedure for performing endotoxin testing on elixir formulations using the Limulus Amebocyte Lysate (LAL) test to ensure compliance with pharmacopoeial and regulatory requirements.

2. Scope

This SOP applies to the Quality Control Department and is intended for use during batch release, in-process verification, and stability testing for elixirs where low endotoxin levels are required, especially for oral solutions administered to immunocompromised patients or products labeled “pyrogen-free.”

3. Responsibilities

  • QC Analyst:
    • Perform endotoxin testing as per the validated method and ensure the sample is free from interference.
    • Ensure all observations are recorded promptly and accurately.
  • QC Supervisor:
    • Verify compliance with reagent, instrument, and method controls.
    • Review results and approve data entry.
  • QA Officer:
    • Ensure regulatory compliance and sign off for batch release or deviation if limits are exceeded.
See also  Elixir Department: SOP for Digital Weighing Balance Usage - V 2.0

4. Accountability

The QC Head is accountable for proper execution and integrity of the endotoxin

test. The QA Head is responsible for ensuring regulatory and GMP compliance for product release.

5. Procedure

5.1 Equipment and Materials

  • LAL test kit (gel clot, chromogenic, or turbidimetric type)
  • Depyrogenated glassware and instruments
  • Endotoxin-free water
  • Positive control endotoxin standard
  • Water bath or incubator at 37±1°C

5.2 Sample Handling

  1. Ensure samples and equipment are handled in an endotoxin-free environment (e.g., LAF cabinet).
  2. Prepare appropriate dilutions using LAL reagent water to minimize interference from sample matrix (e.g., alcohol, preservatives, colors).

5.3 Method Overview

  1. Gel Clot Method: Preferred for qualitative analysis. Results are based on clot formation at a specified sensitivity (e.g., 0.25 EU/mL).
  2. Chromogenic/Turbidimetric Methods: Used for quantitative results. Requires a kinetic reader and calibration curve.
  3. Follow manufacturer’s instructions for the LAL kit in use.

See also  Elixir Department: SOP for Filtering Through Stainless Steel Screens - V 2.0

5.4 Controls and Validity

  1. Include positive product control (PPC), negative product control (NPC), positive control (CSE), and reagent blank.
  2. The test is valid only if:
    • Blank shows no reaction.
    • PPC gives accurate spike recovery (50–200%).
    • Standard endotoxin response falls within the acceptable range.

5.5 Interpretation of Results

  1. Gel Clot: Presence of firm clot indicates positive result (fails limit); absence of clot = negative (passes).
  2. Quantitative Methods: Results are expressed in EU/mL or EU/g. Product must comply with labeled or pharmacopeial limit (e.g., NMT 0.5 EU/mL).

5.6 Acceptance Criteria

  1. Result must be below the endotoxin limit specified in the product monograph or validated specification (e.g., NMT 0.5 EU/mL for oral liquids if specified).
  2. Out-of-specification (OOS) results must be investigated as per deviation SOP.

5.7 Documentation

  1. Record all raw data, including dilution, lot numbers of kits, and observations in the Endotoxin Test Logbook (Annexure-1).
  2. Maintain calibration certificates for LAL reader and qualification reports.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • LAL: Limulus Amebocyte Lysate
  • EU: Endotoxin Units
  • PPC: Positive Product Control
  • NPC: Negative Product Control
  • CSE: Control Standard Endotoxin
See also  Elixir Department: SOP for Operation of Level Control Valves - V 2.0

7. Documents

  1. Endotoxin Test Logbook (Annexure-1)
  2. Batch Manufacturing Record (BMR)
  3. Instrument Calibration and Qualification Records

8. References

  • USP Chapter <85> – Bacterial Endotoxins Test
  • ICH Q6A – Specifications: Test Procedures and Acceptance Criteria
  • 21 CFR Part 211.160 – Laboratory Controls

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Endotoxin Test Logbook

Date Batch No. Dilution Method Result (EU/mL) Limit Pass/Fail Tested By Verified By
11/04/2025 ELX-0425-047 1:10 Gel Clot <0.25 0.5 Pass Rajesh Kumar Sunita Reddy

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial SOP Release New SOP Creation QA Head
11/04/2025 2.0 Included quantitative LAL methods and acceptance criteria Regulatory Alignment QA Head
Elixers V 2.0 Tags:Elixir colorants, Elixir dosage form, Elixir filtration techniques, Elixir flavoring agents, Elixir formulation, Elixir GMP compliance, Elixir manufacturing process, Elixir manufacturing SOPs, Elixir packaging requirements, Elixir pharmacopoeial standards, Elixir preparation methods, Elixir preservatives, Elixir production equipment, Elixir quality control, Elixir regulatory guidelines, Elixir shelf life, Elixir stability testing, Elixir sterilization methods, Elixir storage conditions, Elixir sweetening agents, Elixir viscosity modifiers, Hydroalcoholic solutions, Medicated elixirs, Non-medicated elixirs, Pharmaceutical elixirs

Post navigation

Previous Post: Analytical Method Development: SOP for Management of Reference Standards and Working Standards – V 2.0
Next Post: Analytical Method Development: SOP for Qualification of Glassware Used in AMD – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version